Speakers: Helen Zgurskaya, Professor, University of Oklahoma (USA) Ruben Hartkoorn, Director of Research, Institut Pasteur de Lille (France) Timothy Opperman, Senior Research Scientist, Microbiotix (USA) Moderator: Laura Piddock, Scientific Director, GARDP (Switzerland) Presentation 1: Deciphering antibiotic resistance: Efflux pumps in bacteria (Helen Zgurskaya) Presentation 2: Discovery of efflux pump inhibitors effective against multi-drug resistant Gram-negative bacteria (Ruben Hartkoorn) Presentation 3: Overcoming the pitfalls of the past to discover clinically useful efflux inhibito ..read more

Pre-conference workshop: ‘Milestone-driven R&D – opportunities and challenges’  8th AMR Conference, 5-7 March 2024, Basel, Switzerland Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Speakers: Malcolm Page, Formerly F. Hoffmann-La Roche, Switzerland   Kenneth Bradley, F. Hoffmann-La Roche, Switzerland   Jointly organized by ..read more

Speakers: Kenneth Bradley, Global Head, Infectious Disease Discovery, Roche (Switzerland) Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden) Moderator: Karen Bush, Professor of Practice in Biotechnology, Emerita, Indiana University (USA) Presentation 1: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an industry view (Ken Bradley) Drug discovery starts and ends with the patient. Target product profiles (TPPs) guide R&D. Target candidate profiles (TCPs) provide guidance and enable Go/NoGo decision making for preclini ..read more

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP was not involved in the development of this drug and is not resp ..read more

Day 1 Session 1 Session 2 Session 3 Session 4 Session 1 Session 2 Session 3 Session 4 Introductory remarks Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer Session 1 – Keynote presentation Chair: Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer The Quirks of EUCAST: what to consider when hoping for breakpoints for a new agent – from EUCAST and others Professor Gunnar Kahlmeter, Professor of Clinical bacteriology & Head of the EUCAST Development Laboratory Session 2 – Drug discovery: new targets and new chemistry Chair ..read more

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP was not involved in the development of this drug and is not resp ..read more

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP is not responsible for the content of external sites. Diagnostic te ..read more

Improving access to antibiotics is critical, especially in LMICs where antibiotic shortages are often a huge challenge.  Economic and procurement tools have the potential to remove critical barriers for both countries and suppliers. Join us for a dynamic webinar to unpack the findings of pioneering work which models the impact of affordable access on LMICs and incentivizes suppliers of antibiotics to enter more markets. SECURE is a joint initiative of the World Health Organization (WHO) and the Global Antibiotic Research & Development Partnership (GARDP). SECURE’s webpage: https://g ..read more

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP was not involved in the development of this drug and is not resp ..read more

Many pharmaceutical companies have exited the antibiotic R&D market in the past few decades and focused instead on more profitable therapeutic areas such as drugs for cancer (sold at high prices) or chronic diseases (taken by individuals for life). Incentives to sustain the R&D of new treatments for bacterial infections take the form of ‘push’ funding and ‘pull’ funding. Some countries have instituted a ‘pull’ funding mechanism, the so called ‘Netflix’ subscription models, and numerous governments and philanthropic foundations provide ‘push’ funding for translational research through ..read more